Submitted by kw643 on Thu, 26/03/2026 - 13:54
A Breakthrough Moment for a New Biotech Player
Alceus Bio has been awarded the prestigious Golden Ticket programme from Pioneer Group and AbbVie—a major endorsement of its potential to reshape cancer treatment. Founded in 2024 by Alexander Evans, Alberto Conti, and Rahul Roychoudhuri, the company brings together expertise rooted in immunology and pathology-driven research to tackle some of the toughest challenges in oncology.
Why This Is Exciting
What makes Alceus Bio stand out is its bold scientific approach. The founding team—drawing on deep experience across immune biology and disease pathology—are building next-generation engineered T-cell therapies designed specifically for solid tumours, an area where traditional treatments often fail.
- Pathology-led innovation: By focusing on the underlying mechanisms of disease, the founders are designing therapies that directly address tumour resistance.
- Next-gen CAR-T platform: Their multimodal approach targets cancer through multiple pathways at once, increasing effectiveness.
- AI meets biology: The company integrates synthetic biology with AI to accelerate discovery and precision in treatment design.
More Than Just an Award
The Golden Ticket offers a powerful springboard for growth, including funding, lab space, and direct access to world-class expertise. This support enables Alceus Bio to rapidly scale its research and move closer to clinical impact. The Golden Ticket provides a significant package of support designed to accelerate the winner’s growth and development. As winner, Alceus Bio will unlock the following opportunities:
- Grant funding from AbbVie
- 12-months rent-free incubation space at one of Pioneer’s state-of-the-art facilities
- Exclusive access to the Pioneer ecosystem – an inspiring community dedicated to advancing visionary ventures
- Tailored support from Pioneer’s Venture Development and Investment teams and AbbVie’s scientific and business executives
- Specialist business coaching from the Pioneer Expert Network
- Access to site events and socials, with opportunities to learn from industry leaders and expand the company’s network within the broader ecosystem
Why It Matters
This win highlights the growing strength of the UK’s biotech ecosystem and the importance of collaboration between startups and global pharma leaders. With a founding team grounded in pathology and immune science, Alceus Bio is not just developing new therapies—it’s rethinking how we design them, bringing a new level of precision and ambition to cancer treatment.
Alexander Evans, Co-Founder and CEO of Alceus Bio, said: “We are honoured to be selected as winners of the Golden Ticket among so many outstanding applicants. This award offers Alceus an exceptional opportunity to access support and guidance from the teams at AbbVie and Pioneer. We are excited to collaborate with both groups as we continue to advance our immune cell programming platform to unlock the full potential of AI-enabled peptide design.”